AlphaMadera's AlphaVal page computes Adaptive Biotechnologies Corporation's fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ADPT as undervalued, fairly valued, or overvalued.

What is Adaptive Biotechnologies Corporation's fair value?

Fair value for ADPT is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ADPT?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ADPT's most recent reported fundamentals.

ADPT - Adaptive Biotechnologies Corporation

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $21.25 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: ADPT has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.